ArticleGynecologic oncology2015

Bevacizumab in recurrent, persistent, or advanced stage carcinoma of the cervix: is it cost-effective?

Neil T Phippen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.